vs
Side-by-side financial comparison of Xiao-I Corp (AIXI) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $11.5M, roughly 1.4× Xiao-I Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -263.9%, a 256.1% gap on every dollar of revenue.
Xiao-i is a Chinese cognitive artificial intelligence enterprise founded in 2001.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
AIXI vs DERM — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $16.1M |
| Net Profit | $-30.4M | $-1.2M |
| Gross Margin | 58.1% | — |
| Operating Margin | -254.9% | -2.8% |
| Net Margin | -263.9% | -7.8% |
| Revenue YoY | — | 27.3% |
| Net Profit YoY | — | -182.0% |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $16.1M | ||
| Q3 25 | — | $17.0M | ||
| Q2 25 | $11.5M | $15.0M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | $33.0M | $14.9M | ||
| Q1 24 | — | $13.0M |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | $-30.4M | $-3.8M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-15.5M | $-3.4M | ||
| Q1 24 | — | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 58.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | 64.5% | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | -9.0% | ||
| Q2 25 | -254.9% | -19.2% | ||
| Q1 25 | — | -25.3% | ||
| Q4 24 | — | 17.7% | ||
| Q3 24 | — | -19.8% | ||
| Q2 24 | -45.0% | -19.7% | ||
| Q1 24 | — | -77.4% |
| Q4 25 | — | -7.8% | ||
| Q3 25 | — | -13.6% | ||
| Q2 25 | -263.9% | -25.3% | ||
| Q1 25 | — | -31.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | — | -16.3% | ||
| Q2 24 | -47.2% | -22.6% | ||
| Q1 24 | — | -80.1% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | $-0.64 | $-0.17 | ||
| Q1 24 | — | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | — | $31.9M |
| Total Assets | $82.4M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.1M | ||
| Q3 25 | — | $24.9M | ||
| Q2 25 | $5.0M | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | $1.8M | $23.9M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | — | $31.9M | ||
| Q3 25 | — | $25.9M | ||
| Q2 25 | — | $19.2M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $11.3M | ||
| Q1 24 | — | $13.0M |
| Q4 25 | — | $94.6M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | $82.4M | $81.2M | ||
| Q1 25 | — | $85.0M | ||
| Q4 24 | — | $80.2M | ||
| Q3 24 | — | $64.0M | ||
| Q2 24 | $87.6M | $65.2M | ||
| Q1 24 | — | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-6.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | $-2.3M | $-942.0K | ||
| Q1 25 | — | $-2.8M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-5.2M | ||
| Q1 24 | — | $-5.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIXI
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
